If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Saudi Arabia Business Operation Sale

22 Feb 2024 07:00

RNS Number : 0732E
MyCelx Technologies Corporation
22 February 2024
 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

22 February 2024

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Saudi Arabia Business Operation Sale

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company transforming the environmental impact of industry, is pleased to announce the sale of its Saudi Arabia business operations, including equipment, inventory and contracts, for an acquisition price of up to $7.125 million (the "Total Consideration") to Twarid Water Treatment LLC ("Twarid"), who is owned by Magellan SPV Water Holdings Limited, a company incorporated in Abu Dhabi Global Markets, which in turn is ultimately owned by a Saudi Arabian consortium of investors. The Total Consideration is split $3.125 million at closing with up to $4 million deferred on an earn-out structure. 

 

The earn-out period of 24 months starts immediately, and is based on Twarid achieving revenue results similar to the Company's historic performance in the country. The assets being sold have a net book value of $2.1 million, and the Saudi Arabian business contributed 64% of consolidated group gross profit for the year ended 2022.

 

The sale allows the Company to continue to grow its proprietary media and product sales in Saudi Arabia, through an exclusive distribution agreement with Twarid, whilst relinquishing financial and operational obligations in-country.

 

As part of the Company's strategic plans, the proceeds of the sale will enable the Company to focus on accelerating its marketing and sales plan for its unique technologies in the Perfluoroalkyl and Polyfluoroalkyl Substances ("PFAS") remediation and Enhanced Oil Recovery ("EOR") markets. The Board believes that these large, lucrative opportunities will deliver long term value and sustainable growth by leveraging MYCELX's differentiated and environmentally effective solutions.

 

The Company is confident that its well-established Saudi Arabian business will continue to thrive under the legacy leadership, which the Company expects will transfer to Twarid along with current employees. Their focus will be growing media sales in the oil and gas, waste management, air, marine and PFAS remediation markets in support of Saudi Arabia's Vision 2030 sustainability goals.

 

Closing is subject to certain customary conditions, and is expected to take place by 31 March 2024.

 

Connie Mixon, CEO, commented:

 

"We are delighted to announce the sale of our Saudi Arabia business operations to Twarid. We have operated in Saudi Arabia for many years now and it has been an important part of our growth. This agreement enables MYCELX to continue to grow its proprietary media and products in an important market while relinquishing sales and operations associated with its current Saudi Arabian business.

 

This is a key step in the Company's efforts to place greater marketing and sales resources on its exciting growth markets, PFAS and EOR, while still being able to capitalize on strong demand for its offering in Saudi Arabia. We look forward to working with Twarid as the Saudi business potentially gains even greater market presence and as we focus resources on driving success in PFAS and EOR. These markets are large, global opportunities that will bring long-term value to the Company and where we can deliver innovative solutions with a positive impact on the environment."

 

For further information, please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Ana Ercegovic

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISQLLBLZLLFBBD
Date   Source Headline
14th Oct 20217:00 amRNSMiddle East Contract Win
29th Sep 20217:00 amRNSHalf Year Results Statement
31st Aug 20217:00 amRNSNotice of Interim Results & Investor Presentation
11th Aug 20217:00 amRNSHolding(s) in Company
4th Aug 20217:00 amRNSContract Award and Contract Extension
7th Jul 20215:41 pmRNSResult of AGM
4th Jun 20218:00 amRNSMailing of Annual Financial Report and AM Notice
26th May 20217:00 amRNSFinal Results for the year ending 31 December 2020
19th May 20217:00 amRNSInvestor Presentation
14th May 20217:00 amRNSPFAS System Validation
13th Apr 20211:49 pmRNSGrant of Options
23rd Mar 20217:00 amRNSBoard Changes
17th Mar 20213:37 pmRNSHolding(s) in Company
17th Mar 20212:35 pmRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSTrading Update
18th Feb 20217:00 amRNSSale of MYCELX property in Duluth, USA
17th Feb 20214:32 pmRNSHolding(s) in Company
5th Jan 20212:32 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSHolding(s) in Company
27th Oct 20202:55 pmRNSResult of Annual Meeting
2nd Oct 20202:56 pmRNSNotice of Annual Meeting
22nd Sep 20207:00 amRNSHalf Year Results Statement
4th Sep 20207:00 amRNSAppointment of Nominated Adviser and Sole Broker
7th Aug 202011:50 amRNSDirector/PDMR Shareholding
22nd Jun 20207:00 amRNSContract extension with SABIC
19th Jun 20207:00 amRNSAnnual Financial Report
27th May 20207:00 amRNSFinal Results for the year ending 31 December 2019
11th May 20207:00 amRNSNew Project Award
14th Apr 20207:00 amRNSTrading Update
9th Mar 20207:00 amRNSClosure of Restricted Stock Line
5th Mar 20207:00 amRNSTrading Update
13th Dec 201910:25 amRNSBlock listing Interim Review
4th Nov 20197:00 amRNSTrading Update
16th Sep 20197:00 amRNSHalf Year Results Statement
20th Aug 201912:42 pmRNSHolding(s) in Company
16th Aug 20193:02 pmRNSDirector Shareholding
29th Jul 20197:00 amRNSDirectorate Changes
26th Jul 20197:00 amRNSAppointment of Nominated Adviser & Broker
22nd Jul 20191:34 pmRNSHolding(s) in Company
10th Jul 201912:57 pmRNSResult of Annual Meeting
14th Jun 20197:00 amRNSTrading Update
11th Jun 20197:00 amRNSBlock listing Interim Review
6th Jun 20197:00 amRNSIssue of Equity
31st May 20191:57 pmRNSAnnual Financial Report
13th May 20197:00 amRNSFinal Results for the year ending 31 December 2018
28th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
13th Mar 20197:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.